PATENT CLAIM ANALYSIS

Application Number: 16259167
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-07
Patent Classification: ["424", "152100"]

Abstract:
The invention is directed to methods of treatment of Alzheimer's disease and other tauopathies, via the administration of antibodies having specificity to abnormal forms of tau protein, the antibodies showing no binding and/or reactivity to a normal tau protein and being administered under conditions and in amounts effective to prevent or treat Alzheimer's disease or other tauopathies. In certain embodiments, the antibodies are selective for soluble truncated tau protein truncated at (i) its C-terminus after the glutamic acid residue Glu391, or (ii) at the aspartic acid residue Asp421, or (iii) at its N-terminus at the aspartic acid residue Asp13, or (iv) a combination of (i)-(iii). Further aspects of the invention are directed to the administration of an immunogen comprising an abnormal tau, preferably a soluble truncated tau.

Claim (Index 85):
The method of  claim 84 , wherein the abnormal tau is phosphorylated at Ser413.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 99.0
- Lexical Diversity: 1.98701
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13363214', '15207836', '16188489', '12813297', '13458609']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7436352006040245
- 35 USC 102 Novelty (BERT): 0.6030799310435863
- Combined Prediction Score: 0.7295796736479807
- Mean Citation Score: 362.110288
- Max Citation Score: 685.71924
- Similarity Product: 432.5853811789799

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test